FDA Approves Atezolizumab Combo for Frontline TNBC
The FDA has approved the frontline combination of atezolizumab plus nab-paclitaxel for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer.
Related Articles
Dr McCann on the Ongoing Development of Tailored Treatment Regimens in HER2+ Breast Cancer
Kelly E. McCann, MD, PhD, discusses several targeted approaches under investigation in HER2-positive breast cancer.
OncLive – Clinical Oncology News, Cancer Expert Insights
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Zimberelimab Plus Lenvatinib Shows Activity in ICI-Pretreated Advanced Cervical Cancer
The combination of zimberelimab and lenvatinib had antitumor activity and a manageable safety profile in pretreated advanced cervical cancer.
Afuresertib Plus Paclitaxel Does Not Elicit Substantial Clinical Benefit in Platinum-Resistant Ovarian Cancer
Afuresertib combined with paclitaxel did not elicit PFS or OS benefits vs paclitaxel alone in patients with unselected platinum-resistant ovarian cancer.
Olaparib After Durvalumab/Chemo Boosts PFS in Subgroups of pMMR Endometrial Cancer
Olaparib maintenance following durvalumab plus chemotherapy improved PFS in different subgroups of pMMR endometrial cancer.
Pembrolizumab Plus Concurrent Chemoradiotherapy Improves OS, PFS2 in Advanced Cervical Cancer
The addition of pembrolizumab to chemoradiotherapy prolonged survival and time to second progression in patients with locally advanced cervical cancer.
Cadonilimab Plus Lenvatinib Proves Active in Platinum-Pretreated, Advanced Endometrial Cancer
Cadonilimab plus lenvatinib showed promise as therapy for patients with advanced endometrial cancer and disease progression on prior platinum therapy.
Nivolumab Yields High Clinical CR Rates Allowing for Surgery Omission in dMMR/MSI-H Endometrial Cancer
Nivolumab elicited PR/CRs in all patients treated with resectable dMMR endometrial cancer and no patients experienced disease recurrence during follow-up.
FDA Awards RMAT Designation to NXC-201 for Relapsed/Refractory AL Amyloidosis
The designation underscores the potential of the CAR T-cell therapy NXC-201 to serve as a new option in relapsed/refractory AL amyloidosis.
Illuccix PSMA-PET Imaging Agent Receives UK Approval in Prostate Cancer
The UK Medicines and Healthcare Products Regulatory Agency has approved the kit for the preparation of gallium-68 gozetotide injection.